(This is part one of a two-part series on Warren Adler, his attitudes toward ageism and of the importance of never allowing oneself to lose the creative impulse in the face of aging or rejection.)
Like the tale he so hilariously and sensationally told of divorce through The War of the Roses, author Warren Adler has another story to tell nearly four decades later. He wants people–particularly seniors–to know that older adults are relevant, and as for him, his best work could still be yet to come. After all, the acclaimed author didn’t publish his first novel till he was 46.
“The War of the Roses” Author Warren Adler, 89.
Now 89 and the author of more than 50 novels, including the 1981 tumultuous divorce classic, The War of the Roses (which he adapted into a screenplay of the same name, and the 1989 film that starred Michael Douglas, Kathleen Turner and Danny DeVito), as well as “The Sunset Gang,” his short story series about aging in America, Adler said he isn’t finished yet, and neither should you be.
stock market hours today: Media General, Inc.(MEG)
- [By Monica Gerson]
Media General Inc (NYSE: MEG) is estimated to report its quarterly earnings at $0.04 per share on revenue of $340.17 million.
National Health Investors Inc (NYSE: NHI) is expected to post its quarterly earnings at $1.17 per share on revenue of $57.82 million.
stock market hours today: AMAG Pharmaceuticals, Inc.(AMAG)
- [By WWW.MONEYSHOW.COM]
Makena is the flagship drug from AMAG Pharmaceuticals (AMAG); the drug helps reduce the risk of preterm birth.
The company’s blood registry preserves newborn stem cells used to treat blood and immune disorders.
- [By Lisa Levin]
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) were down around 36 percent to $22.95. Before the open, the issue company issued FY 2017 sales that surrounded current estimates. Also, the company announced an exclusive licensing agreement with Palatin Technologies, Inc. (NYSE: PTN) for North American rights to Rekyndatm. Raymond James downgraded AMAG Pharmaceuticals from Market Perform to Underperform.
stock market hours today: Heartware International, Inc.(HTWR)
- [By Spencer Israel]
4. HeartWare International Inc (NASDAQ: HTWR) – The heart device maker agreed to be acquired by Medtronic for $58 per share in cash two weeks ago. Prior to that the stock had been trading just above $30.
stock market hours today: Novellus Systems Inc.(NVLS)
- [By Chris Lange]
Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.
- [By Lisa Levin]
Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.
- [By Paul Ausick]
Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.
stock market hours today: Tantech Holdings Ltd.(TANH)
- [By Jim Robertson]
On Friday, our Under the Radar Moversnewsletter suggestedshorting small cap China based carbon stock Tantech Holdings Ltd (NASDAQ: TANH):
“The downtrend here is crystal clear; more of the same weakness is there on the earlier part of the chart you can’t see. What’s so compelling about the selloff is yesterday’s bar. The bulls tried to bounce back, but couldn’t… the buyers threw in the towel. TANH peeled back to close closer to the low than the high, and is following through — to the downside — today.”